Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Neo-Adjuvant Cisplatin, Gemcitabine & Bevacizumab, Followed by Radical Cystectomy for Patients With Muscle Invasive, Resectable, Non-Metastatic Transitional Cell Carcinoma (TCC) of the Bladder

NCT00268450 is registered in ClinicalTrials.gov with Medical University of South Carolina as lead sponsor.

NCT NCT00268450
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00268450 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Neo-Adjuvant Cisplatin, Gemcitabine & Bevacizumab, Followed by Radical Cystectomy for Patients With Muscle Invasive, Resectable, Non-Metastatic Transitional Cell Carcinoma (TCC) of the Bladder
Lead sponsor
Medical University of South Carolina
Phase
Phase 2
Overall status
Terminated
Start date
September 21, 2005
Completion date
April 30, 2012
Enrollment
21 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

bladder cancer